{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:56:42Z","timestamp":1786985802197,"version":"build-2736575974"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1274501"],"award-info":[{"award-number":["24CDA1274501"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ccl.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:22:03Z","timestamp":1744644123000},"page":"337-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular-Kidney-Metabolic Health"],"prefix":"10.1016","volume":"43","author":[{"given":"Melinda","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Claudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ccl.2025.03.001_bib1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-2020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.ccl.2025.03.001_bib2","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ccl.2025.03.001_bib3","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ccl.2025.03.001_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ccl.2025.03.001_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197403282901301","article-title":"Accelerated atherosclerosis in prolonged maintenance hemodialysis","volume":"290","author":"Lindner","year":"1974","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.07891109","article-title":"Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes","volume":"5","author":"Plantinga","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.ccl.2025.03.001_bib7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ccl.2025.03.001_bib8","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American heart association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2025.03.001_bib9","article-title":"Metabolic syndrome","author":"Swarup","year":"2024","journal-title":"StatPearls"},{"issue":"5\u20136","key":"10.1016\/j.ccl.2025.03.001_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ccl.2025.03.001_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"4S","key":"10.1016\/j.ccl.2025.03.001_bib12","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.ccl.2025.03.001_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.ccl.2025.03.001_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ccl.2025.03.001_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2024.08.006","article-title":"Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes","author":"Neuen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ccl.2025.03.001_bib16","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1210\/jc.2019-01338","article-title":"Primary prevention of ASCVD and T2DM in patients at metabolic risk: an endocrine society\u2217 clinical practice guideline","volume":"104","author":"Rosenzweig","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ccl.2025.03.001_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC state-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M23-2814","article-title":"Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria","volume":"177","author":"Verma","year":"2024","journal-title":"Ann Intern Med"},{"issue":"9731","key":"10.1016\/j.ccl.2025.03.001_bib19","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccl.2025.03.001_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ejhf.778","article-title":"The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction","volume":"19","author":"Nayor","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.ccl.2025.03.001_bib21","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","article-title":"Novel metabolic risk factors for incident heart failure and their relationship with obesity. The MESA (Multi-Ethnic study of atherosclerosis) study","volume":"51","author":"Bahrami","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ccl.2025.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005685","article-title":"Association of proteinuria and incident atrial fibrillation in patients with intact and reduced kidney function","volume":"6","author":"Molnar","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.ccl.2025.03.001_bib24","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"25 Suppl 2","key":"10.1016\/j.ccl.2025.03.001_bib25","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of cardiology\/American heart association Task Force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jama.2024.12537","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations","volume":"332","author":"Diao","year":"2024","journal-title":"JAMA"},{"issue":"9784","key":"10.1016\/j.ccl.2025.03.001_bib27","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Landray FRCP","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2025.03.001_bib28","article-title":"Enhancing clinical service design for multimorbidity management: a comprehensive approach to joined-up care for diabetes, chronic kidney disease, and heart failure","author":"Al-Chalabi","year":"2024","journal-title":"Diabet Med"},{"issue":"36","key":"10.1016\/j.ccl.2025.03.001_bib29","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccl.2025.03.001_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"10354","key":"10.1016\/j.ccl.2025.03.001_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2025.03.001_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1251798","article-title":"Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients","volume":"14","author":"Danpanichkul","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.ccl.2025.03.001_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus\u2014a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.ccl.2025.03.001_bib35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2025.03.001_bib91","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ccl.2025.03.001_bib44","article-title":"Finerenone\u2019s impact on major adverse cardiovascular events in chronic kidney disease and type 2 diabetes mellitus: a systematic review","volume":"16","author":"Murugan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ccl.2025.03.001_bib84","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ccl.2025.03.001_bib43","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2025.03.001_bib85","article-title":"Nature Medicine nature medicine Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ccl.2025.03.001_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ccl.2025.03.001_bib86","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ccl.2025.03.001_bib45","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2025.03.001_bib87","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2023","journal-title":"NEJM Evidence"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib88","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2025.03.001_bib67","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ccl.2025.03.001_bib89","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2025.03.001_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2025.03.001_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ccl.2025.03.001_bib49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2025.03.001_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ccl.2025.03.001_bib71","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ccl.2025.03.001_bib81","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ccl.2025.03.001_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib80","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib36","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ccl.2025.03.001_bib39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ccl.2025.03.001_bib40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ccl.2025.03.001_bib41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ccl.2025.03.001_bib42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ccl.2025.03.001_bib47","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on kidney outcomes across baseline cardiovascular-kidney-metabolic conditions: a systematic review and meta- analyses","author":"Siddiqi","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.ccl.2025.03.001_bib51","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2025.03.001_bib52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"9386","key":"10.1016\/j.ccl.2025.03.001_bib53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.ccl.2025.03.001_bib54","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ccl.2025.03.001_bib55","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ccl.2025.03.001_bib56","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2025.03.001_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ccl.2025.03.001_bib58","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2025.03.001_bib59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11906-013-0354-3","article-title":"Aldosterone mediates cardiac fibrosis in the setting of hypertension","volume":"15","author":"Azibani","year":"2013","journal-title":"Curr Hypertens Rep"},{"issue":"14","key":"10.1016\/j.ccl.2025.03.001_bib61","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2025.03.001_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ccl.2025.03.001_bib63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ccl.2025.03.001_bib64","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ccl.2025.03.001_bib65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","article-title":"Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults","volume":"37","author":"Armani","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ccl.2025.03.001_bib66","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","author":"Tuttle","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ccl.2025.03.001_bib70","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccl.2025.03.001_bib72","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"Mcmurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ccl.2025.03.001_bib73","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"10208","key":"10.1016\/j.ccl.2025.03.001_bib74","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"41","key":"10.1016\/j.ccl.2025.03.001_bib75","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccl.2025.03.001_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10242","article-title":"Mineral and electrolyte disorders with SGLT2i therapy","volume":"3","author":"Cianciolo","year":"2019","journal-title":"JBMR Plus"},{"issue":"31","key":"10.1016\/j.ccl.2025.03.001_bib77","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccl.2025.03.001_bib78","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2025.03.001_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ccl.2025.03.001_bib82","article-title":"Cardiovascular, kidney and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2025.03.001_bib83","doi-asserted-by":"crossref","first-page":"e2412437","DOI":"10.1001\/jamanetworkopen.2024.12437","article-title":"Medicare coverage and patient out-of-pocket costs for cardiovascular-kidney-metabolic medications","volume":"7","author":"Young","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865125000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865125000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:19:14Z","timestamp":1762309154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865125000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0733865125000050"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2025.03.001","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular-Kidney-Metabolic Health","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}